Skip to content

Chronic Kidney Disease Clinical Decision Support

A Technology-Driven Intervention to Improve Identification and Management of Chronic Kidney Disease in Primary Care

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03890588
Acronym
CKD-CDS
Enrollment
6295
Registered
2019-03-26
Start date
2019-04-17
Completion date
2021-09-29
Last updated
2022-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, Diabetes, Hypertension

Keywords

Chronic Kidney Disease, CKD, Clinical Decision Support, Diabetes, Hypertension

Brief summary

To prevent serious chronic kidney disease (CKD) complications such as end-stage renal disease and cardiovascular events, better strategies are needed to identify, treat, and refer CKD patients seen in primary care clinics. This project expands an existing and successful Web-based clinical decision support (CDS) system to include key elements of CKD care and rigorously assesses the impact of this intervention on quality of CKD care for patients seen in primary care settings, including better recognition of CKD, better management of blood pressure and glucose, and more timely referral to nephrologists when appropriate. This low-cost and highly scalable intervention has high potential to improve CKD care and translate massive public and private sector investments in health informatics into tangible health benefits for large numbers of patients with CKD.

Detailed description

Clinics are randomly allocated 1:1 through a computer-generated program to either control or intervention. Control Clinics. All control clinics will continue to use the basic Electronic Medical Record (EMR)-linked CDS for cardiovascular (CV) risk factor management. This CDS includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. The basic CDS does not include information specific to CKD care. Intervention Clinics. The CKD-CDS intervention provides updated clinical recommendations at any primary care visit for patients meeting inclusion and exclusion criteria. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CKD-CDS intervention is rooted in a series of antecedent studies that developed more limited but successful forms of CDS. From an operational point of view, implementing CKD-CDS at intervention clinics requires a series of 4 distinct steps that occur at every encounter: Step 1: Data exchange and evaluation: The EMR securely exchanges data with the Web Service at every encounter of patients aged 18-75 triggered by BP entry. Step 2: Recognition of CKD and presence of care deficits: Patients with stage 3-4 CKD are automatically identified by the Web Service and evaluated using algorithms maintained in the Web service for identification of CKD and for the 5 emphasized care gaps (identification of CKD, BP control, glucose control, Angiotensin converting enzyme inhibitor (ACEI)/Angiotensin receptor blocker (ARB) use if appropriate, and nephrology consultation if appropriate). If the patient has a care gap, the rooming staff receives an immediate best practice advisory (BPA) prompt to print CDS materials for the patient and the provider to review and use for shared decision making. Using a sequence of steps successfully implemented in previous studies, the rooming staff will print the materials and give the lay version to the patient to review while waiting for the provider. A professional version is left on the door for the provider to review before entering the exam room. This approach has been well-liked by our providers to help them be prepared and to engage patients in their care needs before the clinician-patient interaction. PCPs can also optionally view an electronic version of the CDS materials. The CDS can be viewed in real time for any patient by clicking on a button programmed in the EMR encounter display. Step 3: Use of CKD-CDS recommendations as shared decision-making tools: The participating providers and all rooming staff in the intervention clinics will be trained in the use of the PCP (professional) and patient (low-literacy) versions of the CKD-CDS. For this study, the CDS tool will be adapted to emphasize CKD and, for each identified deficit in CKD care, the CKD-CDS will display patient-specific recommendations consistent with then-current national CKD clinical guidelines; for example: (a) recognize CKD and ask the PCP to enter a CKD diagnosis on the problem list if indicated, and/or (b) specific considerations for how to modify BP control, glucose control, or ACEI/ARB therapy, and/or (c) refer certain patients to nephrology when referral criteria are met. The PCP assesses patient preference for any of the CKD-related treatment options. If the patient wants to act on 1 or more, the PCP can address it then or schedule a subsequent visit for that purpose. If the patient is not interested in any option, no further action is needed at that day's visit. The decision support provided to the PCP is very specific and, if pharmacotherapy is indicated, decision support specifies either initiation or titration of specific drugs based on the drugs/doses the patient is currently taking, distance from goal, and other clinical considerations outlined above. The patient version of the CKD-CDS uses symbols to provide easy patient recognition of priority clinical areas and then suggests potential treatment options they can discuss with their provider. Presenting key CKD care recommendations when indicated (all of which are evidence based and capable of improving CKD care) allows the patient freedom to select his or her preferred treatment option from among several potentially beneficial treatment options. Because patient readiness to take health-related actions varies across specific actions, offering several options improves the chance that a given patient may be interested in addressing at least 1 of the evidence-based options presented. Moreover, patient readiness to act is a key predictor of subsequent adherence and success of treatment, as we have previously shown in this patient population. It is important to realize that the printed page the patient receives frames the discussion to a set of prioritized evidence-based treatment options with likely benefit to the patient. Step 4. Take action based on the decisions made: After discussing with the patient, the provider can then go ahead and order the recommendations suggested by the CDS such as labs, medication, e-consults with nephrology, and referrals to specialists. All actions taken are also based on the provider's clinical judgement.

Interventions

OTHERCKD enhanced clinical decision support

The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
HealthPartners Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Clinic level cluster randomized study

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18 to 75 years, inclusive. The evidence-based guidelines on which the CDS intervention is based are not applicable outside this age range. 2. Have confirmed CKD based on 2 or more estimated glomerular filtration rate (eGFR) values \<60 cc/min/1.73m2, including the most recent eGFR value and a previous eGFR at least one week prior 3. Have a CKD care component suboptimally managed as defined by one or more of the following: 1. Have two or more BP values from separate encounter dates of \>=130/80 including the most recent BP to the index visit 2. Have an individualized A1C over goal as determined by CDS algorithm criteria of most recent glycated hemoglobin (A1C) \> 7% OR \> 8% if any of the following conditions are identified: cardiovascular disease (CVD) or calculated 10-yr atherosclerotic cardiovascular disease (ASCVD) risk \>30%, cancer, hypoglycemia, cognitive impairment, on 2 or more glycemia medications with insulin, or on 3 or more non-insulin glycemia medications 3. Have most recent eGFR 30-59 with hypertension identified or albumin to creatinine ratio (ACR) \> 30 mg/g and not on an ACEI or ARB 4. Have non-steroidal anti-inflammatory drug (NSAID) other than aspirin on the active medication list 5. Have a eGFR 15-29 or ACR \> 300 mg/g without a nephrology visit in the last 12 months

Exclusion criteria

An individual who meets any of the following criteria will be excluded from receiving the CKD-CDS: 1. Patients enrolled in hospice, 2. Patients with active cancer or undergoing chemotherapy 3. Patients with pregnancy in the last year 4. Patients with end stage renal disease Individuals who meet all inclusion and

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With CKD Diagnosis18-month period post indexNumber of patients who had a CKD diagnosis document in the 18 months post index.
Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB)18-month period post indexNumber of patients who had an Angiotensin-converting enzyme inhibitors (ACEI) or Angiotension II reception blockers (ARB) order in the 18 months post index.
Number of Patients With Optimal Blood Pressure Control18-month period post indexNumber of patients for whom the average of the two most recent blood pressures prior to 18 months post index was \<130/80.
Number of Patients With Optimal Glucose Control1 to 18-month period post indexNumber of patients whose last A1c was \<7% in the 1-18 months post index.
Number of Patients With Referral to Nephrology18-month period post indexNumber of patients who have a referral to nephrology in the 18 months post index.

Countries

United States

Participant flow

Recruitment details

Clinics are randomly allocated 1:1 through a computer-generated program to either control or intervention. Patients who have their index visit at a control clinic are assigned to the usual care group and patients who have their index visit at an intervention clinic are assigned to the CKD-CDS intervention group.

Participants by arm

ArmCount
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention)
Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm. CKD enhanced clinical decision support: The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
2,923
Usual Care
A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
3,372
Total6,295

Baseline characteristics

CharacteristicUsual CareTotalCKD Enhanced Clinical Decision Support (CKD-CDS Intervention)
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2118 Participants3963 Participants1845 Participants
Age, Categorical
Between 18 and 65 years
1254 Participants2332 Participants1078 Participants
CKD Diagnosis1589 Participants2944 Participants1355 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
77 Participants121 Participants44 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3258 Participants6096 Participants2838 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
37 Participants78 Participants41 Participants
Race (NIH/OMB)
American Indian or Alaska Native
16 Participants27 Participants11 Participants
Race (NIH/OMB)
Asian
142 Participants261 Participants119 Participants
Race (NIH/OMB)
Black or African American
250 Participants524 Participants274 Participants
Race (NIH/OMB)
More than one race
7 Participants12 Participants5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
7 Participants10 Participants3 Participants
Race (NIH/OMB)
Unknown or Not Reported
97 Participants169 Participants72 Participants
Race (NIH/OMB)
White
2853 Participants5292 Participants2439 Participants
Region of Enrollment
United States
3372 participants6295 participants2923 participants
Sex: Female, Male
Female
1954 Participants3556 Participants1602 Participants
Sex: Female, Male
Male
1418 Participants2739 Participants1321 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
151 / 2,923175 / 3,372
other
Total, other adverse events
1,039 / 2,9231,100 / 3,372
serious
Total, serious adverse events
541 / 2,923543 / 3,372

Outcome results

Primary

Number of Participants With CKD Diagnosis

Number of patients who had a CKD diagnosis document in the 18 months post index.

Time frame: 18-month period post index

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention)Number of Participants With CKD Diagnosis417 Participants
Usual CareNumber of Participants With CKD Diagnosis389 Participants
p-value: 0.2195% CI: [0.91, 1.51]Mixed Models Analysis
Primary

Number of Patients With Optimal Blood Pressure Control

Number of patients for whom the average of the two most recent blood pressures prior to 18 months post index was \<130/80.

Time frame: 18-month period post index

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention)Number of Patients With Optimal Blood Pressure Control334 Participants
Usual CareNumber of Patients With Optimal Blood Pressure Control388 Participants
p-value: 0.8495% CI: [0.84, 1.15]Mixed Models Analysis
Primary

Number of Patients With Optimal Glucose Control

Number of patients whose last A1c was \<7% in the 1-18 months post index.

Time frame: 1 to 18-month period post index

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention)Number of Patients With Optimal Glucose Control141 Participants
Usual CareNumber of Patients With Optimal Glucose Control159 Participants
p-value: 0.9995% CI: [0.8, 1.24]Mixed Models Analysis
Primary

Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB)

Number of patients who had an Angiotensin-converting enzyme inhibitors (ACEI) or Angiotension II reception blockers (ARB) order in the 18 months post index.

Time frame: 18-month period post index

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention)Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB)151 Participants
Usual CareNumber of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB)192 Participants
p-value: 0.6195% CI: [0.76, 1.18]Mixed Models Analysis
Primary

Number of Patients With Referral to Nephrology

Number of patients who have a referral to nephrology in the 18 months post index.

Time frame: 18-month period post index

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
CKD Enhanced Clinical Decision Support (CKD-CDS Intervention)Number of Patients With Referral to Nephrology92 Participants
Usual CareNumber of Patients With Referral to Nephrology95 Participants
p-value: 0.8695% CI: [0.79, 1.32]Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026